Library / regulatory-reference
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, known by its Polish initials URPL, is Poland's national regulatory authority for medicines, headed by the country's chief pharmaceutical-inspection structure.
Poland is one of Europe's larger pharmaceutical markets with a substantial domestic generic-manufacturing sector, and the office's decisions shape both a major European market and an export-active industry.
How products enter the market
Medicines require marketing authorization through national or European procedures after evaluation of quality, safety and efficacy, and establishments are licensed and inspected under the chief pharmaceutical inspectorate.
Post-market work includes safety monitoring within the European alert network, quality surveillance and recalls, with the inspectorate publishing public alerts.
Regional and international role
The office is a senior member of the European regulatory network, contributing assessments and inspections to shared European work.
Its oversight of a large generic-manufacturing base gives its inspection certificates weight in global supply chains.
Using this profile
The office publishes regulations, registers and alerts in Polish, with English material, through its official portal on the national government platform, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: Poland illustrates the big-market generic producer: a European-network regulator whose domestic industry supplies much of the continent.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.